Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting the Mevalonate Pathway in Cancer

Trends in cancer(2021)10.1016/j.trecan.2020.11.008Source: DataRank Database

Targeting the Mevalonate Pathway in Cancer is a research paper published in Trends in cancer (2021). On theSindex it has a DataRank of 0. It has been cited 158 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access158 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 7.01)OA: greenTopics (72)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

David A. Fruman ORCID,Dennis Juarez ORCID

Live enrichment

PubMed:33358111 PMC:PMC8137523 OpenAlex:https://openalex.org/W3117196393

University of California, Irvine

Grant: T32-GM08620

National Institutes of Health

Grant: T32-CA09054

National Institutes of Health

Grant: R21-CA209341

U.S. Department of Defense

Grant: W81XWH2010867

Leukemia and Lymphoma Society

Grant: 6597-20

NCI NIH HHS

Grant: T32 CA009054

NCI NIH HHS

Grant: R21 CA209341

NIGMS NIH HHS

Grant: T32 GM008620

National Institutes of Health

Grant: 5T32GM008620-23

Medical Scientist Training Program

National Institutes of Health

Grant: 1R21CA209341-01

Repurposing statins to enhance efficacy of BCL-2 antagonists in blood cancer

National Institutes of Health

Grant: 2T32CA009054-16

CARCINOGENESIS

Chao Family Comprehensive Cancer Center

FWCI

7.01

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8137523

publisherhttps://api.elsevier.com/content/article/PII:S2405803320303095?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2405803320303095?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.trecan.2020.11.008

Fields of Study

Cancer, Lipids, and MetabolismLipoproteins and Cardiovascular HealthPlant biochemistry and biosynthesis0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

AnimalsAntineoplastic Combined Chemotherapy ProtocolsCell SurvivalDisease Models, AnimalDiterpenesFeeding BehaviorHumansMevalonic AcidNeoplasmsPinocytosisPolyisoprenyl PhosphatesFood-Drug InteractionsHydroxymethylglutaryl-CoA Reductase InhibitorsAlkyl and Aryl TransferasesCell Line, TumorCell ProliferationFarnesyltranstransferaseMiceMetabolic Networks and PathwaysPrenylation

Keywords

Mevalonate pathwayGeranylgeranylationStatinRepurposingGeranylgeraniolPrenylationLovastatinMedicineBiologyComputational biologyBioinformaticsPharmacologyCholesterolBiochemistryEnzymeMevalonatestatinsCombinationsCell SurvivalOncology and CarcinogenesisMevalonic AcidCell LineFood-Drug InteractionsMicePolyisoprenyl PhosphatesCell Line, TumorNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAnimalsFarnesyltranstransferaseHumansCancerCell ProliferationTumorAlkyl and Aryl TransferasesBiomedical and Clinical SciencesAnimalPreventionFeeding BehaviorDisease Models, AnimalGood Health and Well BeingDisease ModelsPinocytosisDiterpenesHydroxymethylglutaryl-CoA Reductase InhibitorsMetabolic Networks and Pathways

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being